期刊文献+

液相色谱-串联质谱法测定犬血管组织中雷帕霉素的含量

Determination of rapamycin in blood vessel of dogs by LC-MS/MS
原文传递
导出
摘要 目的建立犬血管组织中雷帕霉素含量测定的液相色谱-串联质谱方法。方法采用AgilentZorbax C18(2.1 mm×100 mm,3.5μm)色谱柱,流动相为甲醇-水(含10 mmol.L-1醋酸铵,0.08%甲酸)(85∶15,V/V),流速为0.2 mL.min-1;电喷雾离子源,负离子电离模式,选择性反应监测扫描方式,雷帕霉素和罗红霉素(内标)检测的离子对分别为m/z 936.0→m/z 409.0和m/z 837.0→m/z 679.2。结果雷帕霉素在1~1 500μg.L-1浓度范围内有良好的线性关系(r=0.997 6),最低检测限为0.3μg.L-1,日内、日间精密度(RSD)均小于6.7%,提取回收率在81.8%~86.3%范围内,相对回收率在104.4%~109.8%范围内。结论本法简便、快速、灵敏、准确,可用于测定血管组织中雷帕霉素的含量。 AIM To establish a LC-MS/MS method for the determination of rapamycin in blood vessel tissues of dogs. METHODS The chromatographic separation was performed on Agilent Zorbax Cls (2.1 mm ×100 mm, 3.5μm) column, with a mobile phase of methanol-10mmol. L-lammonium acetate and 0.08% formic acid containing water (85 : 15, V/V), at a flow rate of 0.2 mL.min-1. Negative electrospray ionization (ESI) was employed as the ionization source. single reaction monitoring ( SRM ) Rapamycin and internal standard (roxithromycin) were detected by use of mode (m/z 936.0 →m/z 409.0 and m/z 837.0 →m/z 679.2, respectively).RESULTS The linear concentration range for rapamycin was 1 - 1 500μg·L-1 (r = 0.997 6). The limit of quantitation was 0.3 μg·L-1. Within-day RSD and between-day RSD were all less than 6.7%, the extraction recovery rate was about 81.8% - 86.3% and the relative recovery were all within 104.4% - 109.8%. CONCLUSION The method is simple, fast, sensitive and accurate, and is suitable for the determination of rapamycin in blood vessel tissues.
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2011年第10期777-781,共5页 Chinese Journal of New Drugs and Clinical Remedies
关键词 雷帕霉素 血管 色谱法 高压液相 串联质谱法 rapamycin dogs blood vessel chromatography, high pressure liquid tandem massspectrometry
  • 相关文献

参考文献10

二级参考文献37

  • 1孙忠实,胡维丽.新型免疫抑制剂──FK-506[J].中国新药杂志,1995,4(1):15-19. 被引量:4
  • 2KASTRATI A, DIBRA A, EBERLE S, et al. Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized triMs[J]. JAMA, 2005, 294(7) : 819-825.
  • 3BABAPULLE MN, JOSEPH L, BELISLE P, et al. A hierarchical Bayesian meta-analysis of randomized clinical trials of drugeluting stents[J]. Lancet, 2004, 364(9434): 583-591.
  • 4BRAUN-DULLAEUS RC, MANN M J, SEDDING DG, et al. Cell cycle-dependent regulation of smooth muscle cell activation [J]. Arterioscler Thromb Vase Biol, 2004, 24(5): 845-850.
  • 5WESSELY R, SCHOMIG A, KASTRATI A. Sirolimus and paelitaxel on polymer-based drug-eluting stents: similar but different [J]. J Am Coll Cardiol, 2006, 47(4) : 708-714.
  • 6ABAL M, ANDREU JM, BARASOAIN I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action[J]. Curr Cancer Drug Targets, 2003, 3(3) : 193-203.
  • 7MARKS AR. Sirolimus for the prevention of in-stent restenosis in a coronary artery[J]. N Engl J Med, 2003, 349(14): 1307-1309.
  • 8GERVASONI JE Jr, HINDENBURG AA, VEZERIDIS MP, et a/. An effective in vitro antitumor response against human pancreatic carcinoma with paclitaxel and daunorubicin by induction of both necrosis and apoptosis[J]. Anticancer Res, 2004, 24 (5A) : 2617-2626.
  • 9LEVIN AD, VUKMIROVIC N, HWANG CW, et al. Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel [J]. Proc Natl Acad Sci USA, 2004, 101(25): 9463-9467.
  • 10HWANG CW, LEVIN AD, JONAS M, et al. Thrombosis modulates arterial drug distribution for drug-eluting stents [J]. Circulation, 2005, 111 (13) : 1619-1626.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部